

Review Article

Valvular Heart Disease in Pregnancy

SUJETHRA VASU, KATHLEEN STERGIOPOULOS

Division of Cardiovascular Medicine, Department of Internal Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA

Key words:

Cardiac disease, anticoagulation, women.*Manuscript received:*

November 12, 2008;

Accepted:

February 10, 2009.

Address:

Kathleen Stergiopoulos

*Division of
Cardiovascular Medicine
Stony Brook University
School of Medicine
SUNY Health Sciences
Center T16-080
Stony Brook,
NY 11794-8167, USA
e-mail:
kathleen.stergiopoulos@stonybrook.edu*

The management of valvular heart disease due to congenital or acquired etiologies in pregnant patients can be challenging. There is an elevated incidence of adverse maternal and fetal outcomes in this patient population. The keys to optimizing pregnancy outcomes are accurate diagnosis of the etiology and severity of valve disease, pre-conception evaluation and counseling, and referral of the highest risk women to centers with expertise in the management of these patients. A multidisciplinary team approach may be warranted, with a cardiologist, obstetrician, and obstetric anesthesiologist. The aim of this paper is to provide a comprehensive review of the management of specific valvular lesions in pregnancy and the role of anticoagulation in pregnancy. An understanding of the normal hemodynamic changes and adaptation of pregnancy is required in order to appreciate the effect of valvular lesions.

General considerations***Hemodynamic changes during pregnancy***

Dramatic changes occur in the cardiovascular system during pregnancy. There is a 30-50% increase in cardiac output by the end of the first trimester, which peaks between the second and third trimesters.^{1,2} This increase is primarily due to an increase in stroke volume and in circulating blood volume. During the third trimester, preload reduction may occur due to com-

pression of the inferior *vena cava* by the gravid uterus. In addition, there is a 15-20% increase in heart rate, which contributes to an increase in cardiac output. However, the placental circulation offers a decrease in systemic vascular resistance, which can be favorable for certain cardiac lesions.^{1,2}

Hemodynamic changes during labor and delivery

At the time of labor and delivery, there are several changes in the circulatory system that could result in hemodynamic decompensation.^{1,2} There is a further increase in heart rate and blood pressure due to pain and anxiety. Changes in fluid balance resulting from an increase in blood volume during each contraction during labor, as well as a lack of inferior *vena cava* compression contributing to increased preload, both result in a further increase in blood volume, which can result in pulmonary congestion and heart failure.³ The delivery will involve blood loss. Alterations in the hemodynamic status occur most abruptly within the first 12-24 hours after delivery. Thus, it is essential that patients be monitored during this time in the appropriate setting.

Symptoms and signs: normal physical exam in the pregnant patient

The normal physical exam in pregnancy can often mimic disease (Table 1).^{2,4} In-

Table 1. Cardiovascular findings in a normal pregnancy.

Normal history:
Palpitations
Fatigue
Decreased exercise tolerance
Lower extremity edema
Orthopnea
Normal physical exam:
Midsystolic murmur at the left base (flow murmur)
Continuous murmur (mammary souffle)
Split S1
Distended or mildly increased neck veins
Lower extremity edema

creased plasma volume may result in a systolic flow murmur, which can be heard in most normal pregnant patients. This murmur is usually systolic and soft (usually \leq grade II/VI). A venous hum can also be heard, which is usually related to increased mammary blood flow. In normal pregnant patients, echocardiographic changes in the form of mild dilation of the left ventricle and left atrium are commonly seen. Trivial valvular regurgitation is commonly seen in the mitral, tricuspid and pulmonic valves. This may be related to the physiologic hemodynamic changes of pregnancy. In addition, mild tricuspid and mitral annular dilatation may be present, which can contribute to mild valvular regurgitation.²

Prevalence of valve disease in women of child bearing age

Although cardiac disease complicates less than 1% of pregnancies,⁵ it can significantly increase the maternal and fetal risk of adverse outcomes.^{5,6} The development of effective therapy for the treatment of patients during infancy and childhood has resulted in an increased prevalence of adults with congenital heart disease who are of childbearing age (Table 2). Moreover, rheumatic heart disease remains a common disease for patients worldwide, despite an overall decline of the prevalence in Europe and North America.⁷ Other causes of valve disease in younger women are included in Table 2. Prosthetic valves are increasingly seen in women of childbearing age. Those with mechanical prostheses pose unique challenges due to anticoagulation issues. The options for anticoagulation are suboptimal in pregnant women, as will be discussed later in this review. Concerns over accelerated valvular deterioration have been raised in patients

Table 2. Valvular lesions in women of child bearing age.

Valvular regurgitation:
Aortic regurgitation
Congenital (i.e. bicuspid aortic valve)
Rheumatic
Connective tissue disorder (Marfan syndrome)
Mitral regurgitation
Myxomatous
Congenital
Rheumatic
Pulmonic regurgitation
Residual after pulmonic valve balloon valvotomy
Residual after congenital surgical correction (i.e. tetralogy of Fallot)
Valvular stenosis:
Aortic stenosis
Congenital
Rheumatic
Subaortic membrane
Mitral stenosis
Congenital
Rheumatic
Pulmonic stenosis
Congenital
Isolated pulmonic valvar stenosis
Tetralogy of Fallot
Prosthetic valves:
Bioprosthesis
Mechanical

with bioprostheses,⁸ although not all studies have borne this out.⁹

Diagnostic evaluation

The evaluation of patients with cardiovascular disease should ideally begin prior to conception (Table 3),^{2,4} so that appropriate evaluations can be made without putting the fetus or mother at risk. A detailed history and physical exam, assessment of functional capacity, and a 12-lead EKG are essential. Echocardiography is indicated in women with a history of valvular or congenital heart disease, significant dyspnea, any signs of heart failure, any systolic murmur $>$ grade 2, or any diastolic murmur. A complete echocardiogram with Doppler is necessary to identify the etiology and degree of valvular regurgitation and/or stenosis, degree of pulmonary hypertension, and, if present, aortic root dilatation. Importantly, the left ventricular systolic function can also be quantified. Patients with prosthetic valves may benefit from a baseline echocardiogram prior to pregnancy, so that changes in the gradients across a prosthesis can be carefully followed. Exercise stress

Table 3. Pre-conception planning and evaluation

Thorough history of cardiac symptoms including arrhythmias and physical exam
Obtaining records
12-lead electrocardiogram
Baseline exercise tolerance and functional class (exercise testing if needed)
Baseline echocardiogram: <ul style="list-style-type: none"> Etiology and hemodynamics of valvular lesion Assessment of pulmonary artery pressure Assessment of ventricular function
Stability of cardiac hemodynamics over time
Effective contraception until pregnancy desired
Consider valve repair or replacement if symptomatic prior to conception
Adjust medications to prevent adverse fetal events
Genetics referral for patients with heritable cardiac lesion

testing can be useful in order to quantify a patient's functional capacity. However, this should ideally be performed prior to pregnancy. Functional capacity is an important predictor of the ability to tolerate a pregnancy, regardless of the underlying lesion. In women with significant valve disease, the normal hemodynamic changes of pregnancy can precipitate cardiac symptoms in previously stable women, or may exacerbate symptoms in those with mild baseline symptoms.

Table 4 presents a potential risk assessment and management approach during pregnancy.¹⁰ Patients often require frequent monitoring, with a careful history and physical examination, especially if new symptoms develop or if a patient is deemed to be at high risk from a cardiac perspective. Serial echocardiography may be helpful when new signs or symptoms develop. During the antepartum period, patients with mild valvular dis-

Table 4. Risk assessment and management during pregnancy.

Careful frequent history and physical exam at least once per trimester
Change to only necessary medications that are not contraindicated in pregnancy
More frequent monitoring if new symptoms develop
Changes in functional class
Serial echocardiography for any changes in symptoms or signs
Control symptoms with medications, bed rest, and oxygen if necessary
Valvuloplasty if necessary and appropriate
Valve repair or replacement for uncontrolled class III or IV symptoms

ease need to be seen monthly or every other month until 28-30 weeks, after which they may require monitoring every 2 weeks or even weekly. Patients with moderate to severe valvular disease should be seen every 2 weeks until 28-30 weeks, after which they should be seen weekly. Hemodynamic changes intensify after the 26th-28th week, which is the most critical period along with the delivery.

Predictors of high maternal and fetal morbidity

Several studies have assessed the maternal and fetal outcomes of pregnant patients with congenital or acquired valvular disease and have identified important predictors of adverse outcome. Hameed et al¹¹ studied 46 pregnancies in 44 patients with valvular heart disease and found that these patients had marked clinical deterioration and morbid events in the mother (congestive heart failure, need for hospitalization, initiation or increase in cardiac medications and atrial arrhythmias) as well as the fetus (intrauterine growth retardation, low birth weight and prematurity). A clear relationship was found between the severity of mitral or aortic stenosis and adverse maternal and fetal outcomes. Patients with mild mitral or aortic stenosis had outcomes comparable to normal controls. Pre-pregnancy New York Heart Association (NYHA) functional class and the severity of mitral stenosis were the two main predictors of adverse maternal and fetal outcomes.

Leśniak-Sobelga¹² studied 259 pregnancies, all of which had valvular disease (158 with mitral disease, 54 with aortic disease, and 47 with prosthetic heart valves). Mitral stenosis was the most common acquired valve disease. Pregnant patients with critical mitral valve stenosis form a high-risk group who are at significantly increased risk of life-threatening complications. In women with severe aortic stenosis, pregnancy can lead to sudden deterioration. Cardiac complications can be expected in patients with left ventricular enlargement and depressed ventricular systolic function. Factors predicting a successful course of pregnancy and labor in patients with prosthetic valves are adequate left ventricular function, properly functioning valves, and effective anticoagulation.

Siu et al^{5,6} studied 562 pregnancies, with valvular heart disease being the primary cardiac disease in 18% of these. Primary cardiac events were defined as any of the following: pulmonary edema (documented on chest radiograph or by crackles heard over more than one third of the posterior lung fields), sustained sympto-

matic tachyarrhythmia or bradyarrhythmia requiring treatment, stroke, cardiac arrest, or cardiac death. Secondary cardiac events were defined as a decline in NYHA class (≥ 2 classes) compared with baseline, or need for urgent invasive cardiac procedures during pregnancy or within 6 months after delivery. This group identified four predictors of primary cardiac events: prior cardiac event (heart failure, transient ischemic attack, or stroke before pregnancy) or arrhythmia; baseline NYHA class $>II$ or cyanosis; left heart obstruction (mitral valve area <2 cm², aortic valve area <1.5 cm², or peak left ventricular outflow tract gradient >30 mmHg by echocardiography); and reduced systemic ventricular systolic function (ejection fraction $<40\%$). A primary or secondary cardiac event, or both, occurred in 99 pregnancies (17%). The four predictors of primary cardiac events were also predictive of the combined likelihood of either a primary or secondary cardiac event. Five predictors of neonatal events were identified: NYHA class $>II$ or cyanosis during the baseline prenatal visit, maternal left heart obstruction, smoking during pregnancy, multiple gestations, and use of anticoagulants throughout pregnancy.

In a subsequent study of 301 pregnancies, Siu et al⁵ demonstrated the interaction between maternal obstetric and cardiac risk factors in predicting neonatal adverse events. Pregnant women with heart disease are at increased risk for both neonatal and cardiovascular complications. The risk for neonatal adverse events in

pregnant women with heart disease is highest in those with both obstetric (maternal age >35 or <20 years, smoking, multiple gestation) and cardiac (poor maternal functional class, cyanosis, and left heart obstruction) risk factors for neonatal complications. A summary of these findings can be found in Table 5.

Management considerations

Labor and delivery

Multiple studies have shown that vaginal delivery is safe and well tolerated in most patients with cardiovascular disease¹¹⁻¹³ and specifically with valvular heart disease.¹⁴ However, the timing and mode of delivery should be decided upon prior to delivery, jointly with a multidisciplinary team of cardiologists, obstetricians, and obstetric anesthesiologists. For most patients with valvular heart disease, adequate anesthesia and a shortened second stage of labor is safe and can be applied in the majority of patients (Table 6). Cesarean section is potentially associated with a higher rate of complications.¹⁴ It is usually recommended for obstetric indications, and occasionally in a patient with cardiac instability. Hemodynamic monitoring during labor is recommended in symptomatic patients and in patients with moderate or severe valvular stenosis, left ventricular dysfunction, and pulmonary hypertension.

Table 5. Risk stratification for pregnant patients with valvular disease.

High risk of adverse maternal and fetal outcomes:

- Any prior cardiac event or arrhythmia
- NYHA Class >2 or cyanosis
- Systemic ventricular dysfunction (ejection fraction $<40\%$)
- Pulmonary hypertension (PA systolic pressure $>50\%$ systemic pressure), whether isolated or associated with severe valve disease
- Left heart obstruction
 - Severe aortic stenosis (valve area <1 cm², Doppler jet velocity >4 m/s)
 - Symptomatic or severe mitral stenosis
- Severe aortic or mitral regurgitation with NYHA Class III or IV symptoms
- Mechanical prosthetic valve requiring anticoagulation
- Marfan syndrome with or without aortic and mitral regurgitation

Low risk of adverse maternal and fetal outcomes:

- Asymptomatic mild or moderate aortic stenosis (peak gradient <25 mmHg and aortic valve area >1.5 cm²)
- Asymptomatic mild mitral stenosis (MV area >1.5 cm², mean gradient <5 mmHg)
- NYHA functional class I or II, mitral regurgitation with normal LV systolic function (EF $>50\%$)
- NYHA functional class I or II aortic regurgitation with normal LV systolic function
- Regurgitation or stenosis of left heart valve without significant pulmonary hypertension
- Mild or moderate pulmonic stenosis

EF – ejection fraction; MV – mitral valve; NYHA – New York Heart Association; PA – pulmonary artery.

Table 6. Management during labor and delivery.

Short vaginal delivery with excellent anesthesia
Left lateral decubitus position
Cesarean section per obstetric indications
Invasive monitoring if needed
Medical therapy optimization of loading conditions
Treatment of pulmonary edema

Antibiotic prophylaxis

Antibiotic prophylaxis has been indicated in patients with valvular disease at the time of delivery because of the high incidence of bacteremia (and the resultant high maternal and fetal mortality) and the potential risk of endocarditis.^{15,16} However, the most recent American Heart Association/American College of Cardiology practice guidelines for valvular heart disease do not include uncomplicated vaginal or cesarean delivery as an indication for antibiotic prophylaxis.¹⁷ Patients who have a history of endocarditis, a prosthetic cardiac valve, or are within six months of a percutaneous device placement would remain candidates for antibiotic prophylaxis under the 2006 guidelines and 2008 focused update.^{17,18} However, many institutions do not agree with this policy, as the rate of bacteremia may be higher than previously reported.¹⁴ The recommended regimens for antibiotic prophylaxis include ampicillin (2.0 g intramuscular [IM] or intravenous [IV]) plus gentamycin (1.5 mg/kg, not to exceed 120 mg) given at initiation of labor or within 30 minutes of a cesarean section, followed by ampicillin (1 g IM or IV) or amoxicillin (1 g orally) six hours later. For patients who are allergic to ampicillin and amoxicillin, vancomycin can be substituted (1 g IV over 1-2 hours).^{14,17}

Postpartum concerns

Table 7 describes some of the concerns for the postpartum cardiac patient. Medical therapy should be optimized, particularly during the initial 24-48 hours postpartum. A discussion of contraception should take place before the patient leaves the hospital.

Table 7. Postpartum concerns.

Treat anemia
Medical therapy to optimize loading conditions (treatment of pulmonary edema)
Valve repair or replacement
Counseling
Contraception

Specific valve lesions (Figure 1)

Mitral stenosis

Mitral stenosis (MS) is the most common acquired valvular lesion encountered in pregnant women and is almost invariably caused by rheumatic heart disease.^{8,10,14} There is a significant increase in the transmitral gradient during pregnancy due to the increase in the heart rate, circulating blood volume and cardiac output. Patients who were asymptomatic prior to pregnancy can experience dyspnea, decreased exercise capacity, orthopnea, paroxysmal nocturnal dyspnea and pulmonary edema during pregnancy. An increase in left atrial and pulmonary pressures contributes to atrial wall stress and the development of atrial arrhythmias. Both maternal^{5,6,8,19,20} and fetal^{5,6,19} outcomes are directly related to the severity of MS and the pre-pregnancy NYHA functional class. The fetal morbidity (intrauterine growth retardation, low birth weight, prematurity, fetal/neonatal death) has been estimated at approximately 33% in patients with severe MS compared with 28% in patients with moderate MS and 14% in patients with mild MS.¹² Despite the reported morbidity, absolute mortality appears to be low.^{19,21}

Medical therapy

Many patients with moderate or severe mitral stenosis can be managed successfully with medical therapy, which includes strict control of heart rate, volume status and frequent monitoring.^{13,19} The two goals of medical therapy are to reduce the heart rate and reduce the left atrial pressure. Restriction of physical activity effectively reduces the heart rate. Heart rate reduction can be achieved with beta blockers or calcium channel blockers. Metoprolol is the preferred beta blocker, since fetal intrauterine growth retardation, bradycardia and death have been reported with atenolol use.²² Verapamil is preferred over diltiazem, which has been associated with adverse fetal effects. Digoxin can be used in patients with atrial fibrillation for control of ventricular rate and is generally considered safe, well tolerated and has few adverse fetal effects. Reduction of left atrial pressure is achieved by the use of diuretics. However, caution must be exercised to avoid uteroplacental hypoperfusion associated with the use of diuretics, since this is directly related to adverse fetal outcomes. Amiodarone is contraindicated during pregnancy and should not be used for control of ventricular rate.¹⁷ Prophylactic anticoagulation with warfarin or lovenox can be considered for patients with severe left atrial dilation and




Figure 1. A 34-year-old woman, gravida one para zero (G1P0), who presented at 25 weeks pregnant with a murmur. A: Rheumatic mitral stenosis is present. B: Mean forward flow gradient across the mitral valve. C: Moderate aortic regurgitation (rheumatic etiology). D: Mild aortic stenosis is present. E: Moderate tricuspid regurgitation, with top normal pulmonary artery systolic pressure.

severe mitral stenosis despite the presence of sinus rhythm, because of the hypercoagulable state of pregnancy.¹⁷

Hemodynamic monitoring is indicated during labor and delivery in patients with moderate to severe mitral stenosis in order to optimize left atrial pressure and avoid the development of pulmonary edema. Epidural anesthesia is recommended to reduce fluctuations in heart rate and cardiac output. Shortening

of the second stage of labor and assisted delivery is strongly recommended. Most of the studies described above have performed cesarean sections for obstetric indications.

Role of percutaneous balloon mitral valvuloplasty

For patients who are refractory to medical therapy, and remain in NYHA Class III/IV, percutaneous bal-

loon mitral valvuloplasty (PBMV) can be performed during pregnancy. It most commonly necessary after the 28th week of pregnancy. Several studies have demonstrated the efficacy of this procedure in experienced centers.²³⁻²⁷ Most patients return to NYHA I/II and remain in that class until the end of pregnancy. Consequently, there is a significant reduction of maternal morbidity. Complications such as thromboemboli, stroke, pericardial effusion, atrial arrhythmias and new onset mitral regurgitation have been reported. Severe mitral regurgitation requiring mitral valve repair or replacement is rare. Other complications include excessive blood loss, uterine contractions and precipitous labor. In addition, PBMV is associated with some unavoidable exposure to ionizing radiation. Adequate pelvic and abdominal shielding of radiation is necessary. The dose to the fetus is far below the dose at which therapeutic abortion is recommended.¹⁴ The procedure should be avoided in the first trimester and must be performed by experienced operators. Fluoroscopy should be minimized and the procedure should be assisted by echocardiography and Doppler instead. The use of the Inoue balloon catheter (Toray, Houston, Texas) seems to be preferred, in view of its shorter procedure times and hence less radiation exposure for the fetus.¹⁴

Should PBMV be performed prophylactically to improve fetal outcomes?

Patients who have severe mitral stenosis or those who are symptomatic with moderate to severe mitral stenosis should have either PBMV or mitral valve replacement before conception. These patients do very well, having favorable maternal and fetal outcomes with reduced clinical deterioration and reduced need for initiation of pharmacologic therapy.^{5,13,19}

Several studies have documented excellent fetal outcomes with normal growth and development at long-term follow up after PBMV.^{23,25-28} However, other studies have shown no difference in fetal outcomes, despite improvement of maternal functional class and hemodynamics.^{24,29-31} Although prematurity has been linked to the onset of hypertension, diabetes and neurocognitive delays, percutaneous balloon mitral valvuloplasty is not recommended to improve fetal outcomes in patients with moderate to severe mitral stenosis. There is still a potential risk to the fetus from unavoidable ionizing radiation, and therefore PBMV is not recommended for prophylactic use during pregnancy. This procedure is currently reserved only for medically re-

fractory patients with moderate to severe mitral stenosis.

Mitral valve surgery

Studies have compared the efficacy of PBMV and open mitral commissurotomy, as well as the associated maternal and fetal outcomes. Although both strategies appear to be efficacious, the fetal mortality is up to 35% with open mitral commissurotomy.²² Specific predictors of adverse fetal outcomes have not been identified.^{25,31} Given the high maternal morbidity and fetal mortality of surgery, PBMV is recommended as the procedure of choice in patients with favorable valve anatomy. In a review of the outcome of cardiovascular surgery in pregnant women from 1984-1996, a 9% maternal mortality and 29% fetal or neonatal mortality was reported.¹⁴ The duration of pregnancy at the time of surgery, length of cardiopulmonary bypass, and temperature apparently did not influence fetal or neonatal outcome.

Mitral regurgitation

The most common etiologies of mitral regurgitation in the pregnant woman are mitral valve prolapse and rheumatic heart disease. Mitral regurgitation without left ventricular dysfunction is well tolerated during pregnancy because of the fall in the systemic vascular resistance with the addition of the placental circulation.^{11,12} The mainstay of management in patients who are symptomatic due to mitral regurgitation and left ventricular dysfunction is afterload reduction and diuretics. Afterload reduction is not indicated in patients with normal or low blood pressure. Hydralazine and nitrates are safe and well tolerated.¹⁷ Angiotensin-converting-enzyme inhibitors as well as angiotensin receptor blockers are highly teratogenic and therefore contraindicated during pregnancy.²²

Aortic stenosis

Congenital aortic stenosis (AS) is the most common cause of aortic stenosis in pregnant patients. Rheumatic aortic valve disease is less common and frequently occurs in combination with mitral valve disease. Cases with subvalvular and supra-valvular AS during pregnancy have been reported.⁵ Most patients with mild to moderate AS have favorable pregnancy outcomes.^{11,12} In fact, patients with a valve area >1.0 cm² tolerate pregnancy well, provided early diagnosis and close follow up is ensured. However, patients

with moderate and severe aortic stenosis can deteriorate rapidly, with the development of congestive heart failure (44% of patients), arrhythmias (25%), need to commence or increase cardiac medications (33%), and hospitalization (33%).¹¹ Maternal mortality is rare. In addition, an increased incidence of fetal intrauterine growth retardation, respiratory distress, prematurity and low birth weight has been observed in mothers with moderate or severe AS.

Patients with severe AS, or those who are symptomatic with AS and desire a pregnancy, should undergo balloon valvuloplasty or valve replacement prior to conception. The medical management of severe AS during pregnancy is suboptimal, and mainly involves diuretics. In patients with medically refractory severe symptoms, termination of the pregnancy, if early, or repair of the valve by either percutaneous balloon valvuloplasty^{32,33} or valve replacement,³⁴ should be considered. Due to the high fetal mortality with aortic valve replacement, balloon aortic valvuloplasty is preferred.

Hemodynamic monitoring is strongly recommended for labor and delivery in patients with moderate to severe aortic stenosis.¹⁴ Vaginal delivery is preferred with an assisted second stage of labor.³² Silversides et al³² reported that 67% of patients were successfully delivered vaginally in a total of 49 pregnancies in women with aortic stenosis, with cesarean delivery in the remainder. Epidural and spinal anesthesia should be used with caution, given the risk of lowering the systemic vascular resistance, which is poorly tolerated in patients with moderate or severe AS. General anesthesia remains the preferred technique for cesarean section in patients with aortic stenosis.³⁵

Aortic regurgitation

Aortic regurgitation may be due to a congenital bicuspid valve, previous endocarditis, rheumatic heart disease or aortic annular dilation.^{14,36} As in the case of mitral regurgitation, aortic regurgitation without left ventricular dysfunction is usually well tolerated, since the placental circulation contributes to a decrease in afterload. The higher resting heart rate during pregnancy shortens diastolic time and hence the degree of regurgitation. In symptomatic patients with severe aortic regurgitation and left ventricular dysfunction, management includes salt restriction, afterload reduction, diuretics and digoxin. Hydralazine and nitrates can be used for afterload reduction. Asymptomatic patients with severe aortic regurgitation and normal left ventricular systolic function who desire a pregnancy will do

well and should not be considered for prophylactic valve surgery prior to pregnancy.

Pulmonic stenosis

The etiology of pulmonic stenosis is mostly congenital and valvular, although it can be subvalvular, supra-valvular, or the result of homograft deterioration as part of a Ross procedure. Patients with severe pulmonic stenosis have maternal and fetal outcomes comparable to normal controls, according to limited data.^{37,38} Balloon valvuloplasty is rarely indicated in a pregnant patient with pulmonic stenosis. Vaginal delivery is usually safe and well tolerated.

Prosthetic valve considerations

Selection of prosthetic valve in women of childbearing age

The selection of a prosthetic heart valve in women of childbearing age remains challenging and needs to be individualized. The bileaflet mechanical valves offer a superior record of durability, an excellent hemodynamic profile, and a relatively small risk of bleeding and thromboembolic complications with careful anticoagulation.¹⁷ Durability is a major factor in young patients. However, if compliance with anticoagulation is a concern, or for those patients in whom close follow up is not possible, a tissue prosthesis is an option. Deterioration of bioprosthetic heart valves during pregnancy has been reported in several studies, but has not been confirmed by others.^{39,40} Although most available data might suggest accelerated structural valve deterioration in pregnancy, this may also reflect the well established deterioration of tissue valves in young individuals.

Anticoagulation in a pregnant patient with prosthetic heart valve

Anticoagulation is a major difficulty in the management of a pregnant patient with a mechanical prosthesis.³⁹ Anticoagulation poses significant risks to the pregnant woman (uterine hemorrhage) and to the fetus (abortion, fetal loss, intraventricular hemorrhage and embryopathy if warfarin is used). However, the risks of maternal thromboembolism and death are high with inadequate anticoagulation, especially in the hypercoagulable setting of pregnancy (Figure 2). The hypercoagulable state appears to be due to decreased activity of proteins C and S.^{39,41} This is of par-





Figure 2. A 36-year-old woman, gravida one para zero (G1P0), at 12 weeks gestation, with a history of a St. Jude aortic valve prosthesis, presented with dyspnea on exertion and a new murmur. The patient was anticoagulated with subcutaneous heparin at sub-therapeutic levels of activated partial thromboplastin time. A: Elevated gradient across the aortic mechanical prosthesis (mean gradient 52 mmHg). B: Transesophageal echocardiographic (long axis of the aortic valve prosthesis at 120°) evidence of a thrombus. C: After several days of therapy with intravenous heparin, valvular gradients returned to normal.

ticular importance in patients with atrial fibrillation and mechanical heart valves. The type and position of the valvular prosthesis are of critical importance in the selection of anticoagulation in the pregnant woman.⁴²⁻⁴⁴ Any treatment regimen should be undertaken after full discussion of the risks, benefits, and alternatives with the patient and her family. Patients and families need to understand that there is no optimal approach. Heparin use in the first trimester may be less safe, and may result in valvular thrombosis, bleeding, and/or thromboembolic complications. Moreover, risks to the mother also pose a risk to the fetus. It is difficult to make firm recommendations regarding an anticoagulation strategy, since no randomized trials exist on this subject. One approach to anticoagulation that can be used in pregnant patients, endorsed by the American College of Cardiology/American Heart Association (ACC/AHA) Task Force report in 2006,¹⁷ involves dividing patients into higher risk (history of thromboembolism or an older generation mechanical prosthesis in the mitral position) and low risk (no history of thromboembolism, newer generation mechanical prosthesis) categories. The potential options include: 1) low molecular weight heparin (LMWH) or unfractionated heparin

(UFH) between 6-12 weeks, warfarin with a target INR of 2-3 between week 12-36, and then switching to LMWH or UFH after week 36; 2) dose-adjusted UFH throughout pregnancy (intravenously continuous or subcutaneously); or 3) dose-adjusted LMWH throughout pregnancy. Addition of low dose-aspirin can be considered. These recommendations say that warfarin should be stopped after week 35. In addition, they consider the risk of warfarin embryopathy unacceptable to most women and have suggested an alternative of UFH or LMWH. The most recent recommendations, published in 2008 as part of the American College of Chest Physicians (ACCP) consensus on antithrombotic therapy in pregnancy,⁴⁴ recommend dose-adjusted LMWH twice daily throughout pregnancy, adjusted-dose UFH throughout pregnancy, or one of these two regimens until the thirteenth week, with warfarin substitution until close to delivery prior to restarting UFH or LMWH. The guideline statement recommends that if a patient is deemed to be at very high risk for thromboembolism and there are concerns about the efficacy and safety of LMWH or UFH, warfarin can be continued throughout pregnancy and replaced with LMWH or UFH close to delivery. A thorough discussion of the risks and benefits

should be documented. Elkayam and Bitar³⁹ have combined these two approaches, as shown in Table 8.

Warfarin

Warfarin affords the greatest protection against maternal thromboembolism and death in patients with prosthetic heart valves. Chan et al⁴² performed a systematic overview of the various anticoagulation regimens in 1234 pregnancies in patients with older and newer generation mechanical prostheses. The incidence of maternal thromboembolism was lowest (3.9%) in those given warfarin throughout pregnancy, compared with 9.2% in the regimen receiving heparin in the first trimester followed by anticoagulants and 25% in the regimen using heparin throughout pregnancy. The incidence of maternal death was lowest (1%) in those given warfarin throughout pregnancy, compared with 4.2% in the regimen receiving heparin in the first trimester followed by anticoagulants and 6.7% in the regimen using heparin throughout pregnancy. Warfarin use has been associated with fetal wastage and congenital anomalies, which include nasal hypoplasia and epiphyseal stippling. Furthermore, the incidence of fetal intraventricular hemorrhage—especially during forceps extraction—was high. The incidence of fetal wastage was high (33.6%) in those given warfarin throughout pregnancy, compared with 26.5% in the regimen receiving heparin in the first

trimester followed by warfarin and 42.9% in the regimen using heparin throughout pregnancy.⁴²

The incidence of warfarin embryopathy has been debated, with a wide range of incidences (5-67%) reported in the literature,^{40,42-44} but a range of 4-10% appears to be a reasonable estimate based on the most recent information.^{46,47} However, to most women this is still an unacceptable risk. Some investigators have concluded that the risk of warfarin embryopathy is lower when the daily dose is less than 4 mg.⁴⁸ However, others found the risk of warfarin embryopathy to be independent of warfarin dose.⁴⁹ Warfarin is probably safe during the first 6 weeks. Most women will opt to change to another form of anticoagulation from weeks 6-12 to reduce the risk of warfarin embryopathy. Patients are then switched back to warfarin at week 12, until week 36. Warfarin should be switched to heparin no later than 36 weeks because of the high incidence of premature labor in patients with prosthetic heart valves. Warfarin should be switched over to either continuous UFH, dose-adjusted subcutaneous UFH or dose-adjusted LMWH after the 36th week to avoid bleeding complications during labor and delivery.^{17,44}

Unfractionated heparin

UFH does not cross the placenta and is not teratogenic. There is a lower incidence of fetal complications at the

Table 8. Recommended approach for anticoagulation prophylaxis in women with prosthetic heart valve during pregnancy. Reprinted from reference 53, with permission from Sage Publications.

Higher Risk	Lower Risk
First generation PHV (e.g. Starr-Edwards, Bjork Shiley) in the mitral position, atrial fibrillation, history of TE on anticoagulation	Second generation PHV (e.g. St. Jude Medical, Medtronic-Hall) and any mechanical PHV in the aortic position
Warfarin (INR 2.5–3.5) for 35 weeks, followed by UFH (mid-interval aPTT >2.5) or LMWH (pre-dose anti-Xa ~0.7) + ASA 80–100 mg q.d.	SC UFH (mid-interval aPTT 2.0–3.0) or LMWH (pre-dose anti-Xa ~0.6) for 12 weeks, followed by warfarin (INR 2.5–3.0) for 35 weeks, then SC UFH (mid-interval aPTT 2.0–3.0) or LMWH (pre-dose anti-Xa level ~0.6)
OR	OR
UFH (aPTT 2.5–3.5) or LMWH (pre-dose anti-Xa ~0.7) for 12 weeks, followed by warfarin (INR 2.5–3.5) to 35th week, then UFH (aPTT >2.5) or LMWH (pre-dose anti-Xa~0.7) + ASA 80–100 mg q.d.	SC UFH (mid-interval aPTT 2.0–3.0) or LMWH (pre-dose anti-Xa ~0.6) throughout pregnancy

aPTT – activated partial thromboplastin time; ASA – acetylsalicylic acid; INR – international normalized ratio; LMWH – low molecular weight heparin; PHV – prosthetic heart valve; SC – subcutaneous; TE – thromboembolism; UFH – unfractionated heparin.

expense of an increase in maternal thromboembolism and death. A high incidence of maternal thromboembolism and death has been reported both by Sadler⁵⁰ and Salazar.⁴⁷ These adverse outcomes may be attributed partly to inadequate anticoagulation and lack of monitoring of activated partial thromboplastin time (aPTT). Continuous IV heparin offers more consistent anticoagulation and is recommended in high-risk patients by the ACC/AHA guidelines,¹⁷ but it increases the risk of infection, endocarditis, and osteoporosis. Aggressive dose-adjusted subcutaneous heparin can also be used. The aPTT response to heparin is diminished during pregnancy due to increased levels of factor VIII and fibrinogen. Heparin is given every 12 hours subcutaneously with a mid-interval (6 hours after dosing) aPTT $\geq 2 \times$ control levels. Strict and frequent monitoring is essential.

Low molecular weight heparin

LMWH has been offered as an alternative to heparin. As with UFH, it does not cross the placenta. It offers potential advantages, such as a lower incidence of bleeding complications, less osteoporosis, predictable dose response, superior bioavailability, a longer half-life, and a lower rate of spontaneous abortion when compared to UFH. A higher incidence of maternal thromboembolism and death has been noted.⁵² However, detailed review revealed that these adverse outcomes were related to inadequate dose, lack of monitoring or subtherapeutic anti-Xa levels.^{40,52-54} The prior warning by the manufacturers regarding the use of LMWH in patients with prosthetic heart valves has been rephrased to state that “use of Lovenox for thromboprophylaxis in pregnant women with mechanical heart valves has not been adequately studied.”⁵⁵

The dose requirement for LMWH changes during pregnancy as a result of changes in weight and volume of distribution. As per the ACCP recommendations, the target anti-Xa level 4 hours after dosing is around 1.0 U/ml.^{45,46} Barbour⁵⁷ demonstrated the importance of measuring trough levels, which were subtherapeutic with peak levels of around 1.0 U/ml. Furthermore, pre-dose subtherapeutic anti-Xa levels have been associated with maternal thromboembolism. Therefore, routine measurement and maintenance of trough levels within a range of 0.6 to 0.7 U/ml in patients with prosthetic heart valves is recommended. Elkayam et al³⁹ also recommend measuring peak levels of anti-Xa (<1.5 U/ml) to avoid excessive anticoagulation. LMWH should be withdrawn 18-24

hours prior to elective delivery to reduce the chance of spinal hematoma during epidural catheter insertion.

In summary, the decision regarding the choice of anticoagulation needs to be made after full discussion with patient and family regarding the risks, benefits and alternatives of each regimen.^{58,59}

References

1. van Oppen AC, van der Tweel I, Alsbach GP, Heethaar RM, Bruinse HW. A longitudinal study of maternal hemodynamics during normal pregnancy. *Obstet Gynecol.* 1996; 88: 40-46.
2. Elkayam U. Pregnancy and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, editors. *Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine.* 7th ed. Philadelphia, PA: Elsevier; 2005. p. 1965.
3. Clark SL, Phelan JP, Greenspoon J, Aldahl D, Horenstein J. Labor and delivery in the presence of mitral stenosis: central hemodynamic observations. *Am J Obstet Gynecol.* 1985; 152: 984-988.
4. Elkayam U, Gleicher N. Cardiac evaluation during pregnancy. In: Elkayam U, editor. *Cardiac Problems in Pregnancy.* 3rd ed. New York: Wiley-Liss; 1998. p. 23-33.
5. Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. *Circulation.* 2002; 105: 2179-2184.
6. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation.* 2001; 104: 515-521.
7. Soler-Soler J, Galve E. Worldwide perspective of valve disease. *Heart.* 2000; 83: 721-725.
8. Reimold SC, Rutherford JD. Clinical practice. Valvular heart disease in pregnancy. *N Engl J Med.* 2003; 349: 52-59.
9. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. *J Am Coll Cardiol.* 2005; 46: 291-298.
10. Stout KK, Otto CM. Pregnancy in women with valvular heart disease. *Heart.* 2007; 93: 552-558.
11. Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. *J Am Coll Cardiol.* 2001; 37: 893-899.
12. Leśniak-Sobelga A, Tracz W, Kostkiewicz M, Podolec P, Pasowicz M. Clinical and echocardiographic assessment of pregnant women with valvular heart diseases – maternal and fetal outcome. *Int J Cardiol.* 2004; 94: 15-23.
13. Bhatla N, Lal S, Behera G, et al. Cardiac disease in pregnancy. *Int J Gynaecol Obstet.* 2003; 82: 153-159.
14. Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. *J Am Coll Cardiol.* 2005; 46: 223-230.
15. Furman B, Shoham-Vardi I, Bashiri A, Erez O, Mazor M. Clinical significance and outcome of preterm prelabor rupture of membranes: population-based study. *Eur J Obstet Gynecol Reprod Biol.* 2000; 92: 209-216.
16. Campuzano K, Roqué H, Bolnick A, Leo MV, Campbell WA. Bacterial endocarditis complicating pregnancy: case report and systematic review of the literature. *Arch Gynecol Obstet.* 2003; 268: 251-255.

17. Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. *J Am Coll Cardiol.* 2006; 48: e1-148.
18. Nishimura RA, Carabello BA, Faxon DP, et al; American College of Cardiology/American Heart Association Task Force. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2008; 118: 887-896.
19. Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. *Am J Cardiol.* 2003; 91: 1382-1385.
20. Barbosa PJ, Lopes AA, Feitosa GS, et al. Prognostic factors of rheumatic mitral stenosis during pregnancy and puerperium. *Arq Bras Cardiol.* 2000; 75: 215-224.
21. Zelop C, Heffner LF. The downside of cesarean delivery: short- and long-term complications. *Clin Obstet Gynecol.* 2004; 47: 386-393.
22. Cardiovascular drugs in pregnancy. In: Elkayam U, editor. *Cardiac Problems in Pregnancy.* 3rd ed. New York: Wiley-Liss; 1998. p. 339-450.
23. Mangione JA, Lourenço RM, dos Santos ES, et al. Long-term follow-up of pregnant women after percutaneous mitral valvuloplasty. *Catheter Cardiovasc Interv.* 2000; 50: 413-417.
24. Nercolini DC, da Rocha Loures Bueno R, Eduardo Guérios E, et al. Percutaneous mitral balloon valvuloplasty in pregnant women with mitral stenosis. *Catheter Cardiovasc Interv.* 2002; 57: 318-322.
25. de Souza JA, Martinez EE, Ambrose JA, et al. Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy. *J Am Coll Cardiol.* 2001; 37: 900-903.
26. Ben Farhat M, Gamra H, Betbout F, et al. Percutaneous balloon mitral commissurotomy during pregnancy. *Heart.* 1997; 77: 564-567.
27. Esteves CA, Munoz JS, Braga S, et al. Immediate and long-term follow-up of percutaneous balloon mitral valvuloplasty in pregnant patients with rheumatic mitral stenosis. *Am J Cardiol.* 2006; 98: 812-816.
28. Patel JJ, Mitha AS, Hassen F, et al. Percutaneous balloon mitral valvotomy in pregnant patients with tight pliable mitral stenosis. *Am Heart J.* 1993; 125: 1106-1109.
29. Fawzy ME, Kinsara AJ, Stefadouros M, et al. Long-term outcome of mitral balloon valvotomy in pregnant women. *J Heart Valve Dis.* 2001; 10: 153-157.
30. Malhotra M, Sharma JB, Tripathii R, Arora P, Arora R. Maternal and fetal outcome in valvular heart disease. *Int J Gynaecol Obstet.* 2004; 84: 11-16.
31. Weiss Branko M, Von Segesser LK, Alon E, Seifert B, Turina MI. Outcome of cardiovascular surgery and pregnancy, a systematic review of the period 1984-96. *Am J Obstet Gynecol.* 1998; 179: 1643-1653.
32. Silversides CK, Colman JM, Sermer M, Farine D, Siu SC. Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis. *Am J Cardiol.* 2003; 91: 1386-1389.
33. Bhargava B, Agarwal R, Yadav R, Bahl VK, Manchanda SC. Percutaneous balloon aortic valvuloplasty during pregnancy: use of the Inoue balloon and the physiologic antegrade approach. *Cathet Cardiovasc Diagn.* 1998; 45: 422-425.
34. Ben-Ami M, Battino S, Rosenfeld T, Marin G, Shalev E. Aortic valve replacement during pregnancy. A case report and review of the literature. *Acta Obstet Gynecol Scand.* 1990; 69: 651-653.
35. Ramanathan J, D'Alessia JG, Geller E, et al. Analgesia and anesthesia during pregnancy. In: Elkayam U, Gleicher N, editors. *Cardiac Problems in Pregnancy.* New York, NY: Wiley-Liss, 1998; p. 285-313.
36. Lind J, Wallenburg HC. The Marfan syndrome and pregnancy: a retrospective study in a Dutch population. *Eur J Obstet Gynecol Reprod Biol.* 2001; 98: 28-35.
37. Neilson G, Galea EG, Blunt A. Congenital heart disease and pregnancy. *Med J Aust.* 1970; 1: 1086-1088.
38. Hameed A, Yuodim K, Mahboob A, et al. Effect of the severity of pulmonary stenosis on pregnancy outcome: a case control study. *Am J Obstet Gynecol* 2004; 191: 93 (abstr).
39. Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. *J Am Coll Cardiol.* 2005; 46: 403-410.
40. Hung L, Rahimtoola SH. Prosthetic heart valves and pregnancy. *Circulation.* 2003; 107: 1240-1246.
41. de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. *Am J Obstet Gynecol.* 1989; 160: 95-100.
42. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. *Arch Intern Med.* 2000; 160: 191-196.
43. Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. *Am J Med Genet.* 1993; 45: 17-21.
44. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *J Am Coll Cardiol.* 2003; 41: 1633-1652.
45. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008; 133: 844S-886S.
46. Hirsh J, Fuster V, American Heart Association Guide to anticoagulant therapy, part 2: oral anticoagulants. *Circulation.* 1994; 89:1469-1480.
47. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. *J Am Coll Cardiol.* 1996; 27: 1698-1703.
48. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. *J Am Coll Cardiol.* 1999; 33: 1637-1641.
49. Denbow CE, Matadial L, Sivapragasam S, Spencer H. Pregnancy in patients after homograft cardiac valve replacement. *Chest.* 1983; 3: 540-542.
50. Sadler L, McCowan L, White H, Stewart A, Bracken M, North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. *BJOG.* 2000; 107: 245-253.
51. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. *J Am Coll Cardiol.* 1996; 27: 1698-1703.
52. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. *Thromb Haemost.* 2004; 92: 747-751.
53. Elkayam U, Singh H, Irani A, et al. Anticoagulation in preg-

- nant women with prosthetic heart valve. *J Cardiovasc Pharmacol Ther.* 2004; 9: 107-115.
54. McIntock C, North RA, White H. Prosthetic heart valves and pregnancy. *Circulation.* 2003; 108:159-160.
55. Lovenox injection (packet insert). Bridgewater, NJ: Aventis Pharmaceuticals; 2004.
56. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126: 627S-644S.
57. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. *Am J Obstet Gynecol.* 2004; 191: 1024-1029.
58. Spargias K, Manginas A, Pavlides G, et al. Transcatheter aortic valve implantation: first Greek experience. *Hellenic J Cardiol.* 2008; 49: 397-407.
59. Skalidis EI, Vardas PE. Coronary blood flow and flow reserve in aortic stenosis: effect of aortic valve therapy. *Hellenic J Cardiol.* 2008; 49: 379-381.